Roswell Park is boldly pioneering the use of CAR T-cell therapy for solid tumors. This type of cell therapy, a branch of immunotherapy rapidly growing at Roswell Park, is already FDA approved for liquid cancers like leukemia and lymphoma. Now, Roswell Park researchers are preparing for a clinical trial to explore its effectiveness against several kinds of solid tumors including lung cancer. This revolutionary move will lead to discoveries that will shape the way we understand the immune system and ultimately end cancer as we know it.